Basic Principles -- Platelets in Arterial Thrombosis -- The Role of Coagulation in Arterial and Venous Thrombosis -- The Link Between Inflammation and Thrombosis -- The Genetics of Thrombosis -- Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease -- Aspirin in Primary and Secondary Prevention of Cardiovascular Disease -- Thienopyridines in Stable Coronary Disease -- Antithrombotic Therapy for NSTE ACS -- Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction -- Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes -- Direct Thrombin Inhibitors in Acute Coronary Syndromes -- Synthetic Factor Xa Inhibition in Acute Coronary Syndromes -- Antithrombotic Therapy for STEMI -- Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction -- Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction -- Fibrinolysis and Facilitated PCI -- Antithrombotic Therapy in Interventional Cardiology -- Antithrombotic Therapy in Percutaneous Coronary Intervention -- Antithrombotic Therapy in Carotid and Peripheral Intervention -- Monitoring of Antithrombotic Therapies in Interventional Cardiology -- Antithrombotic Therapy in Venous Thromboembolism -- Venous Thromboembolism -- Fibrinolysis for Pulmonary Embolism -- Duration of Anticoagulant Therapy After Venous Thromboembolism -- Clinical Consideration -- Antithrombotic Therapy for Atrial Fibrillation and Cardioversion -- Antithrombotic Therapy for Valvular Heart Disease -- Antithrombotic Therapy in Heart Failure and Cardiomyopathy -- Heparin-Induced Thrombocytopenia -- Resistance to Antiplatelet Drugs.

Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).